A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
PHASE2CompletedINTERVENTIONAL
Enrollment
7
Participants
Timeline
Start Date
March 1, 2021
Primary Completion Date
July 1, 2022
Study Completion Date
September 15, 2022
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG
ORMD-0801 QD
16 mg, QD, two capsules, 8 mg each.
Trial Locations (1)
9000
Universitaire Ziekenhuis Gent, Ghent
All Listed Sponsors
lead
Oramed, Ltd.
INDUSTRY
NCT04616014 - A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter | Biotech Hunter